[go: up one dir, main page]

DE10199054I2 - Hypoglycenisches Agens - Google Patents

Hypoglycenisches Agens

Info

Publication number
DE10199054I2
DE10199054I2 DE2001199054 DE10199054C DE10199054I2 DE 10199054 I2 DE10199054 I2 DE 10199054I2 DE 2001199054 DE2001199054 DE 2001199054 DE 10199054 C DE10199054 C DE 10199054C DE 10199054 I2 DE10199054 I2 DE 10199054I2
Authority
DE
Germany
Prior art keywords
hypoglycene
agent
hypoglycene agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2001199054
Other languages
English (en)
Other versions
DE10199054I1 (de
Inventor
Shigeshi Toyoshima
Yoshiko Seto
Hisashi Shinkai
Koji Toi
Izumi Kumashiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of DE10199054I1 publication Critical patent/DE10199054I1/de
Application granted granted Critical
Publication of DE10199054I2 publication Critical patent/DE10199054I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2001199054 1985-03-27 1986-03-26 Hypoglycenisches Agens Active DE10199054I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6227685 1985-03-27

Publications (2)

Publication Number Publication Date
DE10199054I1 DE10199054I1 (de) 2002-01-10
DE10199054I2 true DE10199054I2 (de) 2006-04-27

Family

ID=13195452

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8686302217T Expired - Lifetime DE3683662D1 (de) 1985-03-27 1986-03-26 Hypoglycemisches agens.
DE2001199054 Active DE10199054I2 (de) 1985-03-27 1986-03-26 Hypoglycenisches Agens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE8686302217T Expired - Lifetime DE3683662D1 (de) 1985-03-27 1986-03-26 Hypoglycemisches agens.

Country Status (4)

Country Link
US (2) US4816484A (de)
EP (1) EP0196222B1 (de)
JP (1) JPS6354321A (de)
DE (2) DE3683662D1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2501432Y2 (ja) * 1990-01-23 1996-06-19 ヤンマー農機株式会社 移植機における苗植え間隔検出装置
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
EP0526171B1 (de) * 1991-07-30 1997-03-05 Ajinomoto Co., Inc. Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5466864A (en) * 1993-02-25 1995-11-14 Ajinomoto Co., Inc. Method for recovering L-phenylalanine
US5831118A (en) * 1996-06-18 1998-11-03 Katayama Seiyakusyo Co., Ltd. Epimerization of 2- or 4- substituted cyclohexanecarboxylic acids
ES2364145T3 (es) 1996-11-15 2011-08-25 Ajinomoto Co., Inc. Composición de nateglinida en comprimidos.
US20040176457A1 (en) * 2003-02-27 2004-09-09 Hemmingsen Lisbeth Tofte Novel NIDDM regimen
EP0991619B1 (de) 1997-06-23 2003-09-10 Tanabe Seiyaku Co., Ltd. Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
BRPI0107715B8 (pt) 2000-01-21 2021-05-25 Novartis Ag produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
MXPA02009130A (es) * 2000-03-17 2003-03-12 Ajinomoto Kk Farmacos para complicaciones de diabetes y neuropatia y utilizacion de los mismos.
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
WO2002032853A1 (fr) 2000-10-18 2002-04-25 Ajinomoto Co.,Inc. Procede de preparation d'acylphenylalanines
CN1232502C (zh) 2000-10-18 2005-12-21 味之素株式会社 那格列胺结晶的制备方法
RU2275354C2 (ru) 2000-10-24 2006-04-27 Адзиномото Ко., Инк. Способы получения кристаллов в-типа натеглинида
MXPA03003686A (es) * 2000-10-24 2004-01-26 Ajinomoto Kk Preparaciones hidrofilas de farmaco que contienen nateglinida.
US6740776B2 (en) 2001-07-16 2004-05-25 Novartis Ag Air oxidation of an aromatic aldehyde to an aromatic acid
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
JP2005519949A (ja) * 2002-03-11 2005-07-07 ノバルティス アクチエンゲゼルシャフト ナテグリニドの塩
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
EP2261202A1 (de) * 2002-04-15 2010-12-15 Ajinomoto Co., Inc. Neue Nateglinide Kristallen
BR0309210A (pt) * 2002-04-15 2005-02-09 Novartis Ag Formas de cristal da n-(trans-4-isopropil ciclohexilcarbonil)-d-fenilalanina
CN100363332C (zh) * 2002-04-26 2008-01-23 中国人民解放军军事医学科学院毒物药物研究所 芳香性氨基酸衍生物，其制备方法及其医药用途
US7314955B2 (en) * 2002-04-29 2008-01-01 Biocon Limited Form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine
ATE495740T1 (de) * 2002-05-28 2011-02-15 Ajinomoto Kk Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung
US20050096367A1 (en) * 2002-05-28 2005-05-05 Yoshiro Kitahara Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
AU2003256454A1 (en) * 2002-07-03 2004-01-23 Teva Pharmaceutical Industries Ltd. Process for preparing nateglinide and intermediates thereof
US6861553B2 (en) * 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) * 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) * 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
WO2004009532A1 (en) * 2002-07-18 2004-01-29 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20050075400A1 (en) * 2002-07-18 2005-04-07 Ronit Yahalomi Polymorphic forms of nateglinide
WO2004067495A1 (fr) * 2003-01-28 2004-08-12 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Composes d'alanine, leur procede de preparation et leur utilisation
WO2004074330A1 (ja) * 2003-02-18 2004-09-02 Konishi Co., Ltd. 硬化性樹脂、その製造方法及び硬化性樹脂組成物
HU227073B1 (hu) 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
JP2007505059A (ja) * 2003-09-11 2007-03-08 ゾルファイ フルーオル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎ−アシル化合物の製造
PL1675625T3 (pl) 2003-09-17 2013-08-30 Univ Texas Diagnostyka obrazowa komórek beta trzustki oparta na mechanizmie kierowania
WO2005110972A1 (en) * 2004-05-07 2005-11-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
GB0413084D0 (en) * 2004-06-11 2004-07-14 Cipla Ltd Process
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
CN101111266A (zh) * 2005-01-31 2008-01-23 味之素株式会社 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
SI1931350T2 (sl) 2005-09-14 2021-11-30 Takeda Pharmaceutical Company Limited Uporaba inhibitorjev dipeptidil peptidaze
US20090221652A1 (en) * 2005-11-07 2009-09-03 Geesaman Bard J Combinations of metformin and meglitinide
US7615649B2 (en) 2006-01-26 2009-11-10 Iowa State University Research Foundation, Inc, Synthesis of polycyclic procyanidins
KR101399916B1 (ko) * 2006-03-31 2014-05-28 아지노모토 가부시키가이샤 카복실산 클로라이드 화합물의 제조방법
WO2007113650A2 (en) * 2006-04-05 2007-10-11 Cadila Pharmaceuticals Limited A novel and improved process fro the preparation of nateglinide and its polymorph form-h
CN100383114C (zh) * 2006-07-21 2008-04-23 杭州保灵有限公司 一种那格列奈的制备工艺
WO2009137082A1 (en) * 2008-05-08 2009-11-12 Concert Pharmaceuticals, Inc. 4-isopropylcyclohexylcarbonyl amino acid derivatives
WO2010130796A1 (en) 2009-05-15 2010-11-18 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
EP3048100A1 (de) 2009-05-28 2016-07-27 Novartis AG Substituierte aminobuttersäurederivate als neprilysin-inhibitoren
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EP2993169B1 (de) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridin derivate als aldosteron synthase hemmer
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja) 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
DK2531501T3 (en) 2010-02-03 2014-02-24 Takeda Pharmaceutical APOPTOSESIGNALREGULERENDE KINASE 1 inhibitors
KR20130087485A (ko) * 2010-06-14 2013-08-06 씨아이피엘에이 엘티디. 나테글리니드의 제조 방법
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
WO2013066277A1 (en) 2011-11-03 2013-05-10 Mahmut Bilgic Synergic compositions
WO2013077819A1 (en) 2011-11-23 2013-05-30 Mahmut Bilgic Pharmaceutical formulations comprising nateglinide
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
EA201690278A1 (ru) 2013-07-25 2016-06-30 Новартис Аг Циклические полипептиды для лечения сердечной недостаточности
TW201518323A (zh) 2013-07-25 2015-05-16 Novartis Ag 合成ａｐｅｌｉｎ多肽之生物結合物
MX2017009534A (es) 2015-01-23 2018-04-10 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media.
ES2634675T3 (es) 2015-05-20 2017-09-28 Corghi S.P.A. Máquina de equilibrado
JP6720512B2 (ja) * 2015-11-27 2020-07-08 住友化学株式会社 トランス−シクロヘキサンカルボン酸の製造方法
CN108602758B (zh) 2016-02-05 2021-01-26 斯福瑞股份公司 制备反式-4-氨基-1-环己烷基羧酸及其衍生物的方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT377496B (de) * 1981-06-19 1985-03-25 Voith Gmbh J M Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
JPS58189121A (ja) * 1982-04-30 1983-11-04 Ajinomoto Co Inc インシユリン投与賦活剤
EP0093551B1 (de) * 1982-04-30 1991-01-16 Ajinomoto Co., Inc. Pharmazeutische Zusammensetzung

Also Published As

Publication number Publication date
JPS6354321A (ja) 1988-03-08
EP0196222A3 (en) 1988-02-24
US4816484A (en) 1989-03-28
DE3683662D1 (de) 1992-03-12
JPH0415221B2 (de) 1992-03-17
DE10199054I1 (de) 2002-01-10
EP0196222A2 (de) 1986-10-01
USRE34878E (en) 1995-03-14
EP0196222B1 (de) 1992-01-29

Similar Documents

Publication Publication Date Title
DE10199054I2 (de) Hypoglycenisches Agens
NO174014C (no) Borehullroemmer
DK153042C (da) Kaeledyrsfoder
DK158986A (da) Invalide-hejsevaerk
DK16986A (da) Gnaverfaelde
DK566386A (da) Vandtaarn
SE449275B (sv) Strombegrensare
FR2591414B1 (fr) Cultivateur-aerateur
DK482886D0 (da) Graenthaester
DK362486D0 (da) Cycloalifatiske ketoaminer
DK264386A (da) Brandraer
KR870001932U (ko) 도라이바
DK111685D0 (da) Letvaeskespaerre
KR870007824U (ko) 아이젠
ES286591Y (es) Isopresor tubo-timpanico
ES290457Y (es) Munequera
CA56311S (fr) Stylographe
IT8535847V0 (it) Videoguida
KR870001604U (ko) 자루 걸레
DK395485D0 (da) Sti-finder
DK460185D0 (da) S-aralkyltrithiophosphonat-insekticider
BR8503311A (pt) Cistotomico
DK515185D0 (da) Kogekarsloefter
BR8501720A (pt) Semeadeira-adubadeira
BR8500544A (pt) Bi-telefone